Arvinas (NASDAQ:ARVN) Shares Down 3.3% – Time to Sell?

Arvinas, Inc. (NASDAQ:ARVN)’s share price was down 3.3% during mid-day trading on Thursday . The stock traded as low as $18.09 and last traded at $18.11. Approximately 35,509 shares were traded during trading, a decline of 95% from the average daily volume of 734,522 shares. The stock had previously closed at $18.73.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ARVN shares. Guggenheim reaffirmed a “buy” rating on shares of Arvinas in a research note on Thursday, December 12th. HC Wainwright restated a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research report on Wednesday, December 11th. Stephens started coverage on Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 price objective for the company. BMO Capital Markets cut their target price on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a research note on Wednesday, November 20th. Finally, Oppenheimer decreased their price target on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, Arvinas has an average rating of “Moderate Buy” and an average target price of $63.50.

Arvinas Trading Down 0.4 %

The company has a market capitalization of $1.31 billion, a PE ratio of -4.07 and a beta of 1.82. The company’s 50 day moving average price is $24.20 and its 200-day moving average price is $25.34.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.20. The firm had revenue of $102.40 million for the quarter, compared to analysts’ expectations of $60.56 million. Arvinas’s revenue was up 196.0% on a year-over-year basis. During the same period last year, the firm posted ($1.18) EPS. As a group, analysts predict that Arvinas, Inc. will post -3.22 earnings per share for the current year.

Institutional Trading of Arvinas

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Baker BROS. Advisors LP purchased a new stake in Arvinas during the third quarter worth approximately $9,989,000. Wasatch Advisors LP lifted its holdings in shares of Arvinas by 58.3% during the 3rd quarter. Wasatch Advisors LP now owns 435,943 shares of the company’s stock valued at $10,737,000 after acquiring an additional 160,510 shares in the last quarter. Candriam S.C.A. boosted its position in Arvinas by 32.0% during the 2nd quarter. Candriam S.C.A. now owns 610,458 shares of the company’s stock worth $16,250,000 after purchasing an additional 147,904 shares during the period. Barclays PLC increased its holdings in Arvinas by 198.9% in the 3rd quarter. Barclays PLC now owns 121,699 shares of the company’s stock valued at $2,998,000 after purchasing an additional 80,984 shares in the last quarter. Finally, Magnetar Financial LLC increased its holdings in Arvinas by 112.7% in the 2nd quarter. Magnetar Financial LLC now owns 41,992 shares of the company’s stock valued at $1,118,000 after purchasing an additional 22,245 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.